The 18th Annual Non-Dilutive Funding Summit
The 18th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with directors at ARPA-H, BARDA, SEED, NIA, NHLBI, NIAID, NINDS, and CIRM, so the innovators could learn about non-dilutive funding opportunities for their R&D directly from the funding agencies.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 19th Non-Dilutive Funding Summit will be January 10, 2024.
BARDA: Integration of New Technologies into Medical Countermeasure Development
Biomedical Advanced Research and Development Authority (BARDA)
Together with its industry partners, the Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats. BARDA provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).
BARDA Director of Medical Countermeasures Dr. Robert Johnson
Dr. Robert Johnson is the Director of Medical Countermeasures Programs (MCMP) for the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services. BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures (MCM) – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. As the MCMP Director, Dr. Johnson overseas the MCM development efforts across BARDA. In this role, Dr. Johnson has a focus on incorporating new technologies that can provide a faster pandemic response across multiple threat areas, as well as new partnerships and approaches to ensure sustainment of current and future capabilities.
Dr. Johnson joined BARDA in November of 2017 as the Director for the Influenza and Emerging Infectious Disease Division. In this position, Dr. Johnson led efforts focused on advanced development and manufacturing capacity of medical countermeasures against pandemic influenza and emerging infectious diseases.
In January 2020, Dr. Johnson was named BARDA’s Incident Commander for the COVID-19 Response and was responsible for establishing BARDA’s initial COVID-19 vaccine, therapeutic, and diagnostics portfolio. Under Operation Warp Speed, and later the Countermeasures Acceleration Group (CAG), Dr. Johnson worked closely with HHS-DOD Leadership and product developers to facilitate rapid clinical development, regulatory authorization, and large-scale manufacturing of safe and effective COVID-19 vaccines. From July through December 2021 Dr. Johnson was detailed as Chief Operating Officer of the CAG. In this role, Dr. Johnson managed the procurement and nation-wide distribution of all adult and pediatric COVID-19 vaccines. During this time, Dr. Johnson also oversaw expansion of the CAG to include monoclonal antibody procurement, inventory management, ordering and distribution, and the planning and execution of the nation-wide COVID-19 oral-antiviral ordering, inventory management, distribution, and data collection systems. Dr. Johnson managed the successful transition of the CAG responsibilities to the HHS Coordination Operations and Response Element (H-CORE) when he returned to BARDA as the Director of Medical Countermeasures Programs.
Prior to joining BARDA, Dr. Johnson served for fourteen years in positions of increasing responsibility at the Division of Microbiology and Infectious Diseases within the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Johnson has also previously held positions at Dynport Vaccine Company and Otsuka Pharmaceuticals. He has served as a technical expert to other organizations working in the biodefense and public health sectors, including the Food and Drug Administration and Department of Defense, as well as the World Health Organization.
Dr. Johnson received his Ph.D. from the University of North Carolina, and his B.S. from the University of Idaho.
Reserve Your Place Today
Register Now Free of Charge
For the 19th Annual Non-Dilutive Funding Summit (NDFS)
Wednesday, January 10, 2024
To Join Hundreds of Life Science Industry Leaders
In Learning about Non-Dilutive Funding Opportunities for Your R&D.
Speakers, location, and all other details to be announced.
Register now to receive updates.
Follow us on LinkedIn or request our newsletter to receive:
- News about non-dilutive funding opportunities
- Announcements about conferences with the best partnering for life science professionals
- Discounts for those conferences.